Redx Pharma PLC (AIM: REDX) announced that its primary asset, RXC007, is successfully moving through phase IIa testing, with anticipated results from the idiopathic pulmonary fibrosis research due in the
Redx Pharma plc (AIM:REDX) Collaboration with the Garvan Institute
Redx Announces Collaboration with the Garvan Institute of Medical Research